Chemotherapeutic Management of Soft Tissue Sarcoma

Katherine Thornton

Research output: Contribution to journalReview article

Abstract

Soft tissue sarcomas are a heterogeneous group of connective tissue tumors, with more than 50 different subtypes. Given the heterogeneity, and the relative small numbers of patients, performing large adequately powered clinical trials in which one can glean any overall broad treatment decisions based on outcome is difficult at best. There is controversy on which chemotherapeutic agents to use in the adjuvant and metastatic settings, or even if to use chemotherapy in the adjuvant setting. In the metastatic setting, doxorubicin and ifosfamide have remained the standards of care for more than 20 years. This review discusses the data on chemotherapy for treatment of metastatic sarcomas and the utility of chemotherapy in the adjuvant and neoadjuvant settings. In addition, the utility of newer biologic agents in the treatment for sarcomas is considered.

Original languageEnglish (US)
Pages (from-to)647-660
Number of pages14
JournalSurgical Clinics of North America
Volume88
Issue number3
DOIs
StatePublished - Jun 1 2008

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Chemotherapeutic Management of Soft Tissue Sarcoma'. Together they form a unique fingerprint.

  • Cite this